Periotherapia Raises 575 Million Yen in Series D2 Round

Periotherapia Co., Ltd. (Headquarters: Suita City, Osaka; President and CEO: Eiji Tahara; hereinafter 'Periotherapia') announced on May 26, 2026, that it has raised a total of 575 million yen through the issuance of J-KISS type stock acquisition rights to Mitsubishi UFJ Capital Co., Ltd. (as the general partner of the 'Mitsubishi UFJ Life Science No. 2 Investment Limited Partnership') and Technoscience LLC, as well as through loans from financial institutions. Furthermore, the company has been selected to receive a maximum subsidy of 1.08 billion yen under the 'Drug Discovery Venture Ecosystem Strengthening Project' of the Japan Agency for Medical Research and Development (AMED). Combined with the 575 million yen raised in this round, the total funds secured exceed 1.6 billion yen. Additionally, the cumulative equity financing amount, excluding AMED subsidies and loans, has now exceeded 2.4 billion yen. Periotherapia, a drug discovery venture originating from Osaka University, is advancing the research and development of innovative antibody drugs targeting pathological periostin, based on the vision of 'developing treatments for intractable diseases and delivering our drugs to patients suffering from these conditions as quickly as possible.' This fundraising aims to enhance financial stability by combining equity investment and debt financing, with the objectives of: (1) advancing the ongoing Phase 1/2a trial in Japan and initiating a Phase 1/2a trial in North America; (2) expanding the pipeline for future growth; and (3) strengthening the organizational structure to support clinical development and securing working capital for business growth. Eiji Tahara, President and CEO of Periotherapia, stated: 'With this fundraising, we will demonstrate the overcoming of drug resistance through improvement of the tumor microenvironment in human clinical trials for metastatic/recurrent HER2-negative breast cancer using our candidate drug PT0101. We will also maximize the use of the over 1.6 billion yen secured, including the AMED subsidy, to accelerate global clinical development, including in North America. We view this funding as a crucial step to our next growth stage and will continue to vigorously advance development to deliver new treatment options to those suffering from intractable diseases as soon as possible.' Mikihiko Shinozaki, Deputy General Manager of the Life Science Department at Mitsubishi UFJ Capital Co., Ltd., the lead investor in this round, commented: 'We are pleased to have successfully closed this round thanks to the efforts of all involved. Since the Series A round, we have highly valued the antibody drug targeting pathological periostin developed by the company and have continued to support it financially and operationally. We will continue to leverage the AMED Drug Discovery Venture Ecosystem Strengthening Project and provide even stronger support for the company's efforts to deliver this drug to cancer patients as soon as possible.' Going forward, the company will use these funds to steadily advance clinical development both domestically and internationally, while expanding its pipeline and strengthening its development structure. Pathological periostin, the company's target, is a promising target that enables a therapeutic approach based on a novel mechanism of action for intractable diseases such as treatment-resistant breast cancer, where effective therapeutic targets have been limited. The company has established a pioneering position in this field. The company will continue to aim for the creation of new treatment options for intractable diseases by maximizing the value of its proprietary technology targeting pathological periostin. Periotherapia Co., Ltd. is a drug discovery venture founded in October 2017 by Yoshiaki Taniyama, Director and Specially Appointed Professor at the Department of Advanced Molecular Therapeutics, Osaka University Graduate School of Medicine. The company has elucidated that pathological periostin variants (hereinafter 'pathological periostin'), which have extra proteins added, are involved in various intractable diseases such as breast cancer, diabetic retinopathy, and myocardial infarction, and is developing drugs targeting these variants. Company Name: Periotherapia Co., Ltd. Headquarters: 2-8 Yamadaoka, Suita City, Osaka Representative: Eiji Tahara (President and CEO) Established: October 2, 2017 Business: Research and development of antibody drugs Website: https://periotherapia.co.jp/ Periotherapia Co., Ltd., Public Relations, Takuya Kawaguchi, E-mail: periotherapia@outlook.com